CNTY 108
Alternative Names: CNTY-108Latest Information Update: 17 May 2024
At a glance
- Originator Century Therapeutics
- Class CAR-NK cell therapies; CAR-T cell therapies; Gene therapies
- Mechanism of Action Natural killer cell replacements; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 24 Apr 2024 Early research in Autoimmune disorders in USA (Parenteral) prior to April 2024 (Century Therapeutics pipeline, April 2024)